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Purpose: This is a mono-institutional study of acute and late toxicities and early biochemical 
control of a retrospective series of 75 prostate cancer patients treated with moderate postopera-
tive hypofractionation delivered by helical tomotherapy (HT).
Patients and methods: From April 2013 to June 2017, 75 patients received adjuvant (n=37) or 
salvage (n=38) treatment, delivering to prostate bed a total dose of 63.8 Gy (equivalent dose in 2-Gy 
fractions=67.4 Gy) using 2.2 Gy fractions. Whole-pelvis irradiation was performed in 63% of cases 
(median dose, 49.3 Gy; range, 48–55.1 Gy). Concurrent hormonal therapy was administered in 46% 
of cases. Common Terminology Criteria for Adverse Events (version 4.0) was adopted for acute 
and late genitourinary (GU) and gastrointestinal (GI) toxicity evaluations. Biochemical progression 
was defined as PSA level increase of ≥0.2 or more above the postoperative radiotherapy (RT) nadir.
Results: Acute GU toxicities were as follows: G1 in 46% and G2 in 4%, detecting no G≥3 
events. For GI toxicity, we recorded G1 in 36% and G2 in 18%. With a median follow-up of 
30 months (range, 12–58 months), we found late toxicity G2 GI in 6.6% and G≥2 GU in 5.3%, 
including two patients who underwent surgical incontinence correction. Acute GI≥2 toxicity 
and diabetes were found to be predictive of late GI≥2 toxicity (P=0.04 and P=0.0019). Actuarial 
2- and 3-year biochemical recurrence-free survivals were 88% and 73%, respectively, for the 
entire population.
Conclusion: In our experience, moderate hypofractionated postoperative RT with HT was fea-
sible and safe, with reports of low incidence of toxicity and promising biochemical control rates.
Keywords: prostate neoplasm, radiotherapy, hypofractionation, adjuvant, salvage
Introduction
Prostate cancer (PC) is the most common cancer in European Union in men older 
than 70 years, with a higher incidence in Northern and Western Europe (>200 cases 
per 100,000).1 In localized PC, radiation therapy has an important role in definitive 
or postoperative setting with or without androgen deprivation therapy (ADT). Three 
important randomized trials with long follow-up (SWOG 8794, EORTC 22911, and 
ARO 96–02) reported significant improvements in biochemical recurrence-free survival 
(bRFS) with the use of adjuvant radiotherapy compared to radical prostatectomy alone 
among patients with adverse pathological features.2–4
On the other hand, two of these randomized trials, reporting that more than 40% of 
patients addressed to observation after surgery will not have any recurrence after 10 
years of follow-up, underline the potential risk of overtreating a subgroup of patients 
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exposed to short- and long-term side effects without the 
evidence of a clear benefit in terms of disease control.5,6
In these patients, initial observation after radical prosta-
tectomy may be the correct choice, keeping salvage radiother-
apy (RT) as a useful option in case of biochemical relapse.7
Briganti et al8 recently developed a predictive nomogram 
to recognize patients for early salvage instead of adjuvant 
treatment.
In patients with adverse pathological features, therefore, 
few prospective multicenter randomized trials are currently 
ongoing and evaluating the timing of postoperative treatment 
(early vs deferred) and the duration of hormone therapy (none 
vs short-term vs long-term), aiming to clarify the contrast-
ing evidence currently available from retrospective studies 
with insufficient follow-up or heterogeneous population.9,10
Several retrospective studies investigated the potential of 
dose escalation in the postoperative setting, confirming the 
positive correlation between higher doses and bRFS rates;11–15 
however, the optimal dose still remains controversial. Based 
on the radiobiological properties of PC, as a tumor more sen-
sitive to higher doses per fraction, the growth of modern RT 
techniques lead to the current spread of moderate and extreme 
hypofractionated treatments for the nonsurgical patient.16
However, in contrast to the definitive setting, few data are 
available on hypofractionated postoperative RT.
Herein, we report our preliminary results of postprostatec-
tomy hypofractionation schedule using helical tomotherapy 
(HT; Accuray, Inc., Sunnyvale, CA, USA), which associates 
intensity modulated radiotherapy (IMRT) delivered with a 
helical system with an image guidance system based on daily 
megavoltage computed tomography (CT) scan.
Materials and methods
This is a retrospective mono-institutional analysis of 75 
patients with histologically proven adenocarcinoma of the 
prostate undergoing moderate postoperative hypofractionated 
RT delivered by HT.
Adjuvant treatment, given within 6 months after surgery 
with PSA ≤0.2 ng/mL, was performed in the presence of 
adverse pathological features (extracapsular extension, inva-
sion of seminal vesicles, positive margins, and lymph nodal 
involvement). Salvage therapy was delivered 6 months after 
surgery with PSA ≥0.2 ng/mL.
ADT was administered, according to the discretion of the 
referring urologist, in patients with seminal vesicle invasion, 
nodal involvement, Gleason Score >7, or PSA >20 ng/mL.
This study was approved by the Steering Ethical Commit-
tee Palermo 2. Written informed consent was obtained from 
all patients to review their medical records, as required by the 
institutional review board. All patients’ data are confidential 
and anonymously recorded.
The primary aim was to report the acute and late tox-
icities, and the secondary endpoint was to evaluate early 
biochemical control.
Radiation planning and treatment
All patients underwent a 2.5 mm thickness slice CT simulation. 
Planning CT and treatment were performed with a full bladder 
(500 mL of water was given 30 minutes before the procedure) 
and empty rectum in a supine position with flexed legs posi-
tioned in knee and ankle devices. As organs at risk (OARs), we 
delineated bladder, rectum, small bowel, intestinal cavity, and 
femoral heads. Prostate bed and pelvic lymph nodes clinical 
target volumes (CTV1–CTV2) were delineated using Radia-
tion Therapy Oncology Group consensus guidelines.17,18 The 
planning target volume (PTV) 1 (PTV1) was obtained adding 
to CTV1 a margin of 5 mm in all directions. The CTV2 was 
expanded by 5–7 mm to generate PTV2. Following Ameri-
can Urological Association/American Society for Radiation 
Oncology guidelines,19 recommending a minimum doses of 
64 and 65 Gy
2
 for adjuvant and salvage RTs, respectively, and 
assuming an α/β=1.5 Gy for PC, we adopted 2.2 Gy fractions 
to deliver a total dose of 63.8 Gy (equivalent dose in 2-Gy frac-
tions [EQD
2
]=67.4 Gy) to prostate bed and a median dose of 
49.3 Gy (EQD
2
=45.1 Gy; range, 48–55.1 Gy) in conventional 
fractionation (1.7–1.9 Gy/fx) to the pelvic lymph nodes using 
simultaneous integrated boost (SIB) technique. Pelvic lymph 
nodes irradiation was planned in patients with the following 
pathological features: pN+ and/or lymph nodal dissection <10 
nodes and/or Gleason Score >8.
The dosimetric goal was to cover 95% of PTVs with at 
least 95% of the prescribed dose; OARs planning constraints 
were as follows: V56Gy ≤35% and V60Gy ≤25% for rectum, 
and V55Gy ≤50% and V60Gy ≤30%–35% for bladder. For 
the intestinal cavity, the dose was reduced as low as possible.
Inverse IMRT planning was performed using the Tomo-
therapy (Accuray, Inc.) planning software. Our image guided 
radiotherapy protocol consists of a daily megavoltage com-
puted tomography (MVCT) considering the intrafraction 
variability of OARs to check setup accuracy and to assess 
appropriate bladder filling and rectal emptying.
Toxicity evaluation
The acute and late genitourinary (GU) and gastrointestinal 
(GI) radiation-related toxicities were scored according to the 
Common Terminology Criteria for Adverse Events (CTCAE, 
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version 4.0). Biochemical progression was defined as PSA 
level increase of ≥0.2 or more above the postoperative RT nadir.
Clinical evaluation of acute toxicity was performed 
weekly during the treatment and then at 40 and 90 days 
after the end of RT. Afterward, we evaluated the late events 
every 3–6 months for the first 2 years and then at biannual 
and annual intervals.
statistical analyses
Frequencies and percentages are reported for GU and GI 
toxicities; medians and ranges were calculated for continu-
ous variables. Statistical analyses were performed with chi-
squared tests assuming P≤0.05 as statistically significant. 
Survival curves were generated with Kaplan–Meier method. 
All statistical analyses were carried out using MedCalc statis-
tical software package, version 18.5 (Mariakerke, Belgium).
Results
From April 2013 to June 2017, 75 patients with median age 
of 68 years (range, 54–84 years) were treated with hypo-
fractionated radiation therapy after prostatectomy. Patients’ 
characteristics are summarized in Table 1. Adjuvant treatment 
was performed in 37 (49%) patients and salvage therapy in 38 
(51%) patients. ADT was administered in 34 (46%) patients.
A total dose of 63.8 Gy (EQD
2
=67.4 Gy) to prostate bed 
was delivered. Pelvic lymph nodes irradiation with a median 
dose of 49.3 Gy (range, 48–55.1 Gy) in conventional frac-
tionation was administered in 47 (63%) patients.
All 75 patients completed the planned treatment without 
any interruption, with good tolerance.
Acute GU toxicities were as follows: G1 in 35 (46%) 
and G2 in three (4%) patients, no G≥3 events were detected; 
the main symptom reported was urinary tract pain, which 
occurred in 18 (24%) patients. For GI toxicity, we recorded 
G1 in 36% of patients (n=27) and G2 in 18% of patients 
(n=14). Most frequent GI adverse event was diarrhea in 
19 (25%) cases. Table 2 presents specific acute symptoms 
reported according to CTCAE, version 4.0.
After a median follow-up of 30 months (range, 12–58 
years), we detected G2 GI late toxicity in five (6.6%) cases; 
no G3 toxicity was observed, and G≥2 GU late toxicity was 
observed in four (5.3%) patients, consisting of two G2 late 
events and two G3 patients who underwent surgical incon-
tinence correction after 24 and 36 months, respectively 
(Figure 1).
Also, dosimetric parameters, bladder and rectum V45 
and V60, were not related to acute and late toxicity patterns, 
respectively. Only acute GI G2 toxicity and diabetes were 
found to be predictive of late GI G2 toxicity (P=0.04 and 
P=0.0019, respectively).
In a subgroup analysis, a higher incidence of acute GI 
G2 toxicity in patients who underwent whole-pelvis irradia-
tion was observed, detecting 12 cases (25%) vs two events 
Table 1 Patients’ characteristics
Characteristics Median (range) or n (%)
age (years) 68 (54–84)
Follow-up (months) 30 (12–58)
Diabetes
Yes 17 (23)
no 58 (77)
Psa pre-RT (ng/ml) 0.19 (0–7.03)
gleason score
≤7 58 (77)
≥8 17 (23)
pT
pT2a 1 (2)
pT2b 6 (8)
pT2c 17 (23)
pT3a 22 (29)
pT3b 27 (36)
pT4 1 (2)
pn+
no 63 (84)
Yes 12 (16)
surgical margins
negative 44 (59)
Positive 31 (41)
RT
adjuvant 37 (49)
salvage 38 (51)
Pelvic nodal RT
no 28 (37)
Yes 47 (63)
RT+aDT
no 41 (54)
Yes 34 (46)
Abbreviations: aDT, androgen deprivation therapy; RT, radiotherapy.
Table 2 acute gi and gU adverse events according to the 
CTCae version 4.0 scale
GI symptoms Grade 1 Grade 2 Grade 3
Tenesmus 11 8 –
Diarrhea 15 4 –
Rectal bleeding – 1
hemorrhoids 1 1 –
GU symptoms Grade 1 Grade 2 Grade 3
Urinary tract pain 16 2 –
Urinary frequency 8 – –
incontinence worsening 1 – –
Urgency 7 1 –
Abbreviations: CTCae, Common Terminology Criteria for adverse events; gi, 
gastrointestinal; gU, gastrourinary.
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(7%) in the prostate bed alone subgroup. Actuarial 2- and 
3-year bRFSs were 88% and 73%, respectively, for the entire 
population (Figure 2).
We failed to find any significant correlation among pelvic 
RT (P=0.25), adjuvant or salvage intent (P=0.28), hormone 
therapy (P=0.32), and bRFS rates.
At the time of the analysis, all patients are alive except 
one who died because of cerebrovascular disease.
Discussion
Our clinical experience with postprostatectomy moderate 
hypofractionation using HT confirmed that, with this deliv-
ery technique, toxicities are quite low and similar to those 
observed in other hypofractionation studies in this setting.20
The use of hypofractionation in PC comes from the 
well-known evidence of the very low α/β ratio of the tumor 
that leads to improved tumor control using higher doses per 
fraction.21,22
As these evidences are supported by several randomized 
Phase III trials for the definitive patient,23–25 few studies in 
literature evaluated hypo-RT in the postoperative setting, 
reporting favorable toxicity profiles with very low rates of 
G>2 toxicity (Table 3).26–35
Fersino et al30 reported only one case of acute G3 urinary 
toxicity in their series of 125 patients (64 adjuvant and 61 
salvage) treated with hypofractionated volumetric modulated 
arc therapy (VMAT), and at the time of final assessment, they 
collected no G>2 late toxicity.
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Figure 2 Biochemical relapse-free survival curves for the entire population (A) and stratified for adjuvant and salvage treatment (B).
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Figure 1 g3 toxicity free-survival curves for the entire population (A) and according to radiotherapy volumes (B) (prostate bed only vs prostate bed and whole-pelvis 
irradiation)
Abbreviations: PB, prostate bed; WPi, whole pelvis irradiation.
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Similar results were observed in the study by Massaccesi 
et al27 in their prospective trial of postoperative IMRT to the 
whole pelvis (45 Gy/25fx) plus a SIB of 62.5 Gy/25fx deliv-
ered to the prostate fossa, observing no G>2 acute toxicity 
in their series of 49 patients.
More recently, the same RT schedule was evaluated by 
Macchia et al29 who published data about 124 patients using 
SIB-IMRT technique with concurrent hormonal therapy; with 
a median follow-up of 30 months, the authors observed one 
case of acute G4 urinary adverse event, and 5-year GI and GU 
toxicity rates of 1.1% and 7.3%, respectively; therefore, they 
also collected very promising results in terms of biochemical 
control, with 2- and 3-year bRFS rates of 96.5% and 91.1%, 
respectively, remarking the role of IMRT in improving the 
radiobiological effectiveness of treatment and assuring an 
excellent OARs sparing.
Actually, data on the use of HT in the hypofractionation 
postoperative setting are limited. Katayama et al33 in their 
series of 40 patients treated in the postprostatectomy setting 
with 54 Gy in 18 fractions delivered to prostate bed reported 
excellent data in terms of acute toxicity, with no G3 adverse 
event observed, despite a report on late side effects is cur-
rently lacking.
Kruser et al34 reported only one G3 GU acute toxicity 
event, and no G3 late side effect in their series of 108 patients 
(59 with tomotherapy and 49 with linear accelerator-based 
IMRT) who underwent a hypofractionated schedule of 65 
Gy/2.5 Gy/fx. Similarly, Barra et al35 published their study 
on 64 patients treated with the same schedule, collecting 
only G1 acute GU and GI toxicities and reporting late G3 
GU adverse events only in 3.3% of cases.
Also in our population, the use of HT guaranteed an 
acceptable tolerability, in agreement with other hypofrac-
tionation experiences in this setting.
The interpretation of these findings in the light of other 
published data is challenging due to differences in treatment 
schedules and inhomogeneity of treated population.36
Similar to these and other IMRT studies, in our series, 
there was no association between GU toxicity and clinical or 
dosimetric parameters, although observing GU side effects 
being slightly more severe than GI ones.
Delineation of target volumes may have contributed to our 
side effects patterns, as we adopted Radiation Therapy Oncol-
ogy Group guidelines. Compared to EORTC and FROGG 
guidelines, Radiation Therapy Oncology Group delineates a 
volume of prostate bed CTV encompassing a larger volume 
of bladder, maintaining a significantly lower exposure of 
rectum and mesorectal fascia.37,38 As reported by Ko et al,39 
the vesico-urethral anastomosis represents the most frequent 
site of relapse, and it must be encompassed with posterior 
bladder wall in prostate bed CTV, leading to high exposure 
of normal bladder tissue, with an increased risk both in terms 
of frequency and severity of acute and late GU toxicities.
With regard to GI side effects, in our series, no G3 acute 
or late toxicity was observed as we reported only G2 adverse 
events in 18% and 6%, respectively, and we found diabetes 
and acute GI toxicity to be predictive of late GI toxicity.
Despite the real benefit in terms of clinical outcomes is still 
under debate even for the definitive setting,40,41 we decided to 
treat pelvic lymph nodes for patients at risk of nodal involve-
ment still reporting a higher incidence, yet not statistically 
significant, of GI toxicity, compared to patients not addressed 
to whole-pelvis irradiation (P=0.06). This may be explained 
by the most frequent adoption of a safe schedule of 49.3 Gy 
in conventional fractionation that we mainly applied in pN0 
patients but positive for other histopathological risk factors. 
Longobardi et al42 reported an excellent profile of toxicity both 
in definitive and in postoperative setting, in their series of 178 
patients who underwent whole-pelvis bed irradiation+SIB to 
prostate/prostate with HT.
Our favorable toxicity rates can also be related to our 
prescription dose. Albeit the optimal dose for prostate bed 
still remains controversial,7,31,36 compared to other studies on 
hypofractionated postprostatectomy RT, we adopted a more 
conservative EQD
2
 prescription (67.4 Gy
2
), which allowed 
to reach a curative dose, maintaining a low probability of 
toxicity compared to the 2.5 Gy/fx schedule, which is the 
most reported in literature (Table 3).
Indeed, Cozzarini et al31 investigated late toxicity patterns 
in a mono-institutional cohort of 247 patients treated with 
moderate hypofractionated HT, reporting a higher incidence 
of G3 urinary toxicity in the >2 Gy/fx subgroup. This is one 
of the largest series about late sequelae in postoperative 
prostate hypofractionation, with a median follow-up of 69 
months and G3–4 late urinary incidence of 16.5%. Keeping 
in mind the different schedules adopted in this series (65.8 
Gy/2.35 Gy/fx; 71.4 Gy/2.5–2.6 Gy/fx; and 58 Gy/2.9 Gy/
fx). The authors explained these findings to be due to the 
negative effect of surgery, which does not allow the potential 
of bladder urothelium recovery from radiation-induced dam-
age, resulting in a higher risk of urinary late toxicity when 
doses per fraction >2.55 Gy are used.43
Also different from the study by Cozzarini et al, we 
used a tighter margin of 0.5 cm from CTV to PTV, which is 
considered the minimum recommended when daily online 
image guidance is adopted.44
As in conventional fractionation, the use of image 
guided radiotherapy represents an established tool to lower 
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hypofractionated postoperative helical tomotherapy for prostate cancer
toxicity rates in the postoperative setting as it allows a 
more precise coverage of the target, minimizing OARs 
exposure, with a remarkable improvement of the thera-
peutic ratio.45,46
Consistent with these findings, at the time of the final 
analysis, the impact of our schedule in terms of biochemical 
control reflects in a 3-year bRFS of 73% rate in agreement 
with literature data ranging from 72.9% to 85.5% at 2–3 
years20, confirming the efficacy of our treatment schedule.
The important limitations of our study are the relatively 
low number of patients and short follow-up. Moreover, we 
lack a well-designed quality of life study.
Conclusion
Our clinical experience with moderate postoperative hypo-
fractionation using HT confirms low toxicity rates. In addi-
tion, we found encouraging preliminary data on biochemical 
control. Nevertheless, a longer follow-up is required for 
definitive assessment of clinical outcome.
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